← FDA DRUG APPROVALS

FDA ANDA · ANDA076204

MOEXIPRIL HYDROCHLORIDE

Sponsor: TEVA

APPLICATION
ANDA076204
TYPE
ANDA
ORIGINAL APPROVAL
2003-05-08
LATEST ACTION
2015-04-02
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

MOEXIPRIL HYDROCHLORIDEPrescription
MOEXIPRIL HYDROCHLORIDE 7.5MG · TABLET · ORAL
MOEXIPRIL HYDROCHLORIDEPrescription
MOEXIPRIL HYDROCHLORIDE 15MG · TABLET · ORAL

Approval history

2015-04-02Labeling · Supplement 13 · standardAP
2015-04-02Labeling · Supplement 12AP
2011-11-15Labeling · Supplement 11AP
2010-08-31Labeling · Supplement 9AP
2003-05-08OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →